New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
09:02 EDTBAXBaxter to acquire Chatham Therapeutics
Baxter International and Chatham Therapeutics announced that Baxter has agreed to acquire all of Chatham’s outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia. Under the terms of the agreement, Baxter will make an initial payment of $70M to acquire all of the outstanding membership interests of Chatham. Baxter may make additional payments in the future based on specified development, regulatory and commercial milestones. Baxter will continue the ongoing Phase I/II open-label clinical trial to assess the safety and optimal dosing schedule of BAX 335, an investigational FIX gene therapy treatment for hemophilia B. The BNP technology provides a mechanism for the patient's own liver to begin producing FIX following a single dose of the genetically engineered treatment. The design of the vector allows for more targeted delivery of the FIX therapeutic “cargo” into the natural site of FIX synthesis. This may permit effective therapy with low quantities of the vector. The Phase I/II clinical trial is proceeding as expected and aims to enroll up to 16 hemophilia B patients. Following the acquisition, Chatham will maintain its licensing and development relationship with Asklepios BioPharmaceutical on the development of novel hemophilia therapeutic gene therapy candidates using the Biological Nano Particle platform. AskBio is involved with the development of its proprietary BNPTM gene-delivery platform technology for therapeutics targeting diseases in the heart, CNS, muscle, ocular and liver tissues.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:15 EDTBAXLeerink to hold a conference
Subscribe for More Information
February 2, 2016
09:24 EDTBAXBaxter: 1Q16 should be weakest quarter of FY16
Subscribe for More Information
08:53 EDTBAXBaxter sees FY16 CapEx $900M
Says does not anticipate any sales in 2016 in IPS. Sees FY16 surgical franchise sales growth 2%-3%. Sees FY16 renal business sales growth roughly 3%. Sees FY16 operating margin roughly 11%. Sees FY16 interest expense roughly $90M. Sees FY16 adjusted tax rate 19%-20%. Sees FY16 average share count roughly 540M shares. Sees FY16 CapEx $900M. Sees FY16 free cash flow $500M. Sees FY16 operating cash flow roughly $1.4B. Guidance taken from Q4 earnings conference call.
07:04 EDTBAXBaxter sees FY16 EPS ex-items $1.46-$1.54, consensus $1.42
Subscribe for More Information
07:03 EDTBAXBaxter sees Q1 EPS ex-items 28c-30c, consensus 32c
Subscribe for More Information
07:02 EDTBAXBaxter reports Q4 adjusted EPS 43c, consensus 32c
Subscribe for More Information
February 1, 2016
14:32 EDTBAXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
08:09 EDTBAXOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use